文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向CXCR4的68Ga-pentixafor PET/CT能否作为原发性醛固酮增多症双侧肾上腺病变患者免于肾上腺静脉采血的手术决策与预后预测的可靠手段?

Is CXCR4-targeted 68Ga-pentixafor PET/CT a reliable AVS-free modality for surgical decision-making and prognostic prediction in primary aldosteronism with bilateral adrenal lesions?
PubMed 文献 · EJNMMI Res · 2025-08-28

本研究纳入51例原发性醛固酮增多症伴双侧肾上腺病变患者行68Ga-pentixafor PET/CT,其中36例根据PET/CT偏侧化结果行肾上腺切除术。术后完全生化成功率为91.67%、完全临床成功率为100%,PET/CT结果对术后结局有良好预测价值,86.11%的手术患者病理为肾上腺皮质腺瘤且CYP11B2与CXCR4表达阳性。作者认为该显像可用于手术决策,可能替代肾上腺静脉采血并预测术后生化与临床成功。

要点

  • 51例原发性醛固酮增多症伴双侧肾上腺病变患者行68Ga-pentixafor PET/CT,36例据此确定手术侧。
  • 36例手术患者术后完全生化成功率91.67%、完全临床成功率100%。
  • 86.11%的手术患者病理为肾上腺皮质腺瘤,CYP11B2与CXCR4表达阳性。

核心结论

  • 靶向CXCR4的68Ga-pentixafor PET/CT可有效用于伴双侧肾上腺病变的原发性醛固酮增多症患者的手术决策,可能作为肾上腺静脉采血的替代手段,并可能用于预测术后生化与临床成功。

研究设计与样本

  • 本研究为临床试验(注册号NCT06247566,注册日期2021-11-01),纳入51例原发性醛固酮增多症伴双侧肾上腺病变患者行68Ga-pentixafor PET/CT,其中36例根据PET/CT偏侧化结果行肾上腺切除术。

主要发现

  • 36例手术患者术后完全生化成功率为91.67%,完全临床成功率为100%。
  • 受试者工作特征曲线分析提示PET/CT结果对手术患者术后结局有良好预测价值。
  • 68Ga-pentixafor PET/CT引导手术的患者术后病理显示86.11%为肾上腺皮质腺瘤,且CYP11B2与CXCR4表达阳性。

临床怎么用

  • 作者认为,靶向CXCR4的68Ga-pentixafor PET/CT可有效用于伴双侧肾上腺病变的原发性醛固酮增多症患者的手术决策,可能作为肾上腺静脉采血的替代手段,并可能用于预测术后生化与临床成功。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients diagnosed with primary aldosteronism (PA) accompanied by bilateral adrenal lesions, identifying optimal candidates for surgical intervention remains a significant clinical challenge. Although adrenal venous sampling (AVS) is currently the gold standard for lateralizing aldosterone hypersecretion, its technical complexity, invasiveness, and interpretive difficulties restrict its widespread adoption. In this study, we aimed to investigate the clinical application of 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) as a non-invasive imaging modality in AVS-free surgical decision-making for PA patients with bilateral adrenal lesions. RESULTS: Among the 51 patients who underwent 68Ga-pentixafor PET/CT, 36 patients had adrenalectomy, with the surgical side determined by PET/CT lateralization. The postoperative complete biochemical and clinical success rates for these patients were 91.67% and 100%, respectively. Additionally, receiver operating characteristic curve analysis indicated that PET/CT results were favorable predictors of postoperative outcomes in surgical patients. Postoperative pathological evaluation of 68Ga-pentixafor PET/CT-guided surgical patients revealed that 86.11% had adrenocortical adenomas with positive CYP11B2 and CXCR4 expression. CONCLUSION: CXCR4-targeted 68Ga-pentixafor PET/CT can be effectively utilized in surgery decision-making for PA patients with bilateral adrenal lesions, offering a potential alternative to AVS and maybe applied to predict postoperative biochemical and clinical success. TRIAL REGISTRATION: 68Ga-Pentixafor PET/CT for Guiding Surgical Treatment of Primary Aldosteronism With Bilateral Adrenal Lesions; Trial registration number: NCT06247566; Date of registration: 2021-11-01; URL of trial registry record: https://clinicaltrials.gov/study/NCT06247566 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Shu Z, He Y, Long T, et al. Is CXCR4-targeted 68Ga-pentixafor PET/CT a reliable AVS-free modality for surgical decision-making and prognostic prediction in primary aldosteronism with bilateral adrenal lesions? EJNMMI Res. 2025. PMID: 40875090. doi:10.1186/s13550-025-01309-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。